Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.

Carrieri MP, Leport C, Protopopescu C, Cassuto JP, Bouvet E, Peyramond D, Raffi F, Moatti JP, Chêne G, Spire B.

J Acquir Immune Defic Syndr. 2006 Apr 1;41(4):477-85.

PMID:
16652057
2.

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group.

J Antimicrob Chemother. 2009 Sep;64(3):599-606. doi: 10.1093/jac/dkp232. Epub 2009 Jul 14.

PMID:
19602563
3.

Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study.

Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):385-92.

PMID:
16540942
4.

Evidence-based, multifactorial approach to addressing non-adherence to antiretroviral therapy and improving standards of care.

Herrmann S, McKinnon E, John M, Hyland N, Martinez OP, Cain A, Turner K, Coombs A, Manolikos C, Mallal S.

Intern Med J. 2008 Jan;38(1):8-15. Epub 2007 Oct 3.

PMID:
17916167
5.

Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.

Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network.

Arch Pediatr Adolesc Med. 2005 Aug;159(8):764-70.

PMID:
16061785
6.

Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.

Le Moing V, Chêne G, Leport C, Lewden C, Duran S, Garré M, Masquelier B, Dupon M, Raffi F; Antiprotéases Cohorte (APROCO) Study Group.

Clin Infect Dis. 2002 Jan 15;34(2):239-47. Epub 2001 Dec 4.

PMID:
11740714
7.

Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP; APROCO cohort study group.

Soc Sci Med. 2002 May;54(10):1481-96.

PMID:
12061483
8.
9.

Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women.

Lazo M, Gange SJ, Wilson TE, Anastos K, Ostrow DG, Witt MD, Jacobson LP.

Clin Infect Dis. 2007 Nov 15;45(10):1377-85. Epub 2007 Oct 11.

PMID:
17968839
10.

Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.

Lima VD, Gill VS, Yip B, Hogg RS, Montaner JS, Harrigan PR.

J Infect Dis. 2008 Jul 1;198(1):51-8. doi: 10.1086/588675.

PMID:
18498238
11.

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy.

Duran S, Savès M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C; APROCO Study Group.

AIDS. 2001 Dec 7;15(18):2441-4.

PMID:
11740195
12.

The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.

Villes V, Spire B, Lewden C, Perronne C, Besnier JM, Garré M, Chêne G, Leport C, Carrieri MP, Le Moings V; ANRS CO-8 APROCO-COPILOTE Study Group.

Antivir Ther. 2007;12(7):1067-74.

PMID:
18018765
13.

Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

Gathe JC Jr, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.

Clin Ther. 2006 May;28(5):745-54.

PMID:
16861096
14.

Patterns, predictors, and consequences of initial regimen type among HIV-infected women receiving highly active antiretroviral therapy.

Golub ET, Benning L, Sharma A, Gandhi M, Cohen MH, Young M, Gange SJ.

Clin Infect Dis. 2008 Jan 15;46(2):305-12. doi: 10.1086/524752.

PMID:
18171267
15.

The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.

Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B; MANIF2000 cohort study group.

Addiction. 2008 Nov;103(11):1828-36. doi: 10.1111/j.1360-0443.2008.02323.x. Epub 2008 Sep 4.

PMID:
18778390
17.

Baseline predictors of three types of antiretroviral therapy (ART) adherence: A 2-year follow-up.

Nilsson Schönnesson L, Diamond PM, Ross MW, Williams M, Bratt G.

AIDS Care. 2006 May;18(4):407-14.

PMID:
16809121
18.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
19.

Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial.

Sarna A, Luchters S, Geibel S, Chersich MF, Munyao P, Kaai S, Mandaliya KN, Shikely KS, Temmerman M, Rutenberg N.

J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):611-9. doi: 10.1097/QAI.0b013e3181806bf1.

PMID:
18645509
20.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777

Supplemental Content

Support Center